ETV1 Human siRNA Oligo Duplex (Locus ID 2115)

CAT#: SR301472

ETV1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each

Specifications

Product Data

• Purity: HPLC purified
• Quality Control: Tested by ESI-MS
• Sequences: Available with shipment
• Components: ETV1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 2115)
  Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
  Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
• Stability: One year from date of shipment when stored at -20°C.
• Number of Transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
• Note: Single siRNA duplex (10nmol) can be ordered.

Reference Data

• RefSeq: NM_001163147, NM_001163148, NM_001163149, NM_001163150, NM_001163151, NM_001163152, NM_004956, NR_120445, NM_001370556, NM_001370555
• Synonyms: ER81
• Summary: 'This gene encodes a member of the ETS (E twenty-six) family of transcription factors. The ETS proteins regulate many target genes that modulate biological processes like cell growth, angiogenesis, migration, proliferation and differentiation. All ETS proteins contain an ETS DNA-binding domain that binds to DNA sequences containing the consensus 5'-CGGA[AT]-3'. The protein encoded by this gene contains a conserved short acidic transactivation domain (TAD) in the N-terminal region, in addition to the ETS DNA-binding domain in the C-terminal region. This gene is involved in chromosomal translocations, which result in multiple fusion proteins including EWS-ETV1 in Ewing sarcoma and at least 10 ETV1 partners (see PMID: 19657377, Table 1) in prostate cancer. In addition to chromosomal rearrangement, this gene is overexpressed in prostate cancer, melanoma and gastrointestinal stromal tumor. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2016]'
• Performance Guaranteed: OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
  
  For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).